Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TZP-101 in Severe Diabetic Gastroparesis
NCT00612014Phase 2Completed
- Sponsor
- Tranzyme Pharma
- Start
- Oct 2007
- Primary completion
- Feb 2009
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of ulimorelin in gastroparesis (6 arms), sponsored by Tranzyme Pharma. Primary endpoint: Change from baseline in the mean Gastroparesis Cardinal Symptom Index score at 4 days. Started Oct 2007; status: completed.
02
Drugs
ulimorelin
03
Conditions
gastroparesis
Beyond the preview
Go deeper on NCT00612014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00612014.